e-learning
resources
Vienna 2009
Sunday, 13.09.2009
Respiratory infection caused by Pseudomonas aeruginosa
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Inhaled liposomal ciprofloxacin hydrochloride significantly reduces sputum
pseudomonas aeruginosa
density in non-CF bronchiectasis
D. Bilton, A. DeSoyza, C. Haworth, P. Bruinenberg, B. Otulana (London, Newcastle, Cambridge, United Kingdom; Hayward, United States Of America)
Source:
Annual Congress 2009 - Respiratory infection caused by Pseudomonas aeruginosa
Session:
Respiratory infection caused by Pseudomonas aeruginosa
Session type:
Oral Presentation
Number:
1362
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Bilton, A. DeSoyza, C. Haworth, P. Bruinenberg, B. Otulana (London, Newcastle, Cambridge, United Kingdom; Hayward, United States Of America). Inhaled liposomal ciprofloxacin hydrochloride significantly reduces sputum
pseudomonas aeruginosa
density in non-CF bronchiectasis. Eur Respir J 2009; 34: Suppl. 53, 1362
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Pharmacokinetics and antibacterial activity of inhaled liposomal ciprofloxacin hydrochloride in healthy volunteers and in cystic fibrosis (CF) patients
Source: Annual Congress 2009 - Cystic fibrosis: disease progression and novel therapies
Year: 2009
Distribution of nebulised gentamicin in patients with bronchiectasis
Source: Eur Respir J 2004; 24: Suppl. 48, 640s
Year: 2004
Effects and modulation of release rate of inhaled ciprofloxacin with liposomal formulations in healthy subjects and patients with bronchiectasis
Source: Annual Congress 2010 - New aspects of treatment of lower respiratory tract infections
Year: 2010
Inhaled antibiotics in non-cystic fibrosis bronchiectasis: better than oral antibiotics?
Source: International Congress 2016 – PG13 Inhaled antibiotics in respiratory infections
Year: 2016
Inhaled colistin in elderly patients with bronchiectasis and chronic bronchial infection with pseudomonas
Source: Annual Congress 2012 - Management of severe respiratory infections
Year: 2012
Effect of high dose tobramicin (TOBI®) inhalation on respiratory values in cystic fibrosis
Source: Eur Respir J 2003; 22: Suppl. 45, 503s
Year: 2003
Non-CF bronchiectasis: nebulised colistimethate sodium improves symptoms and bacterial load in sputum of patients with pseudomonas aeruginosa
Source: Annual Congress 2008 - Microbiology and treatment of bronchiectasis and exacerbations of COPD
Year: 2008
Bronchial reactions to the inhalation of high-dose tobramycin in cystic fibrosis
Source: Eur Respir J 2002; 20: 122-126
Year: 2002
Evaluation of inhaled dry powder tobramycin free base in non-cystic fibrosis bronchiectasis patients
Source: International Congress 2016 – Clinical and microbiological aspects of bronchiectasis and non-tuberculous mycobacterium (NTM) infections
Year: 2016
Dual release ciprofloxacin for inhalation (DRCFI) reduces sputum
pseudomonas aeruginosa
(
Pa
) density and delays time to infective pulmonary exacerbation in non-cystic fibrosis (CF) bronchiectasis (BE)
Source: Annual Congress 2011 - Advances in antibiotic therapy of non-cystic fibrosis bronchiectasis
Year: 2011
Montelukast plus inhaled budesonide versus double dose inhaled budesonide in nonasthmatic eosinophilic bronchitis
Source: Annual Congress 2011 - Asthma: control and treatment
Year: 2011
Eradication treatment in Non CF bronchiectasis: The effect of inhaled antibiotics (tobramycin and colistin) on patients with pseudomonas aeruginosa
Source: International Congress 2017 – Clinical update on bronchiectasis and nontuberculous mycobacteria (NTM) infections
Year: 2017
Long-term administration of aerosolised tobramycin in patients with cystic fibrosis
Source: Eur Respir J 2005; 26: Suppl. 49, 619s
Year: 2005
The effect of nebulised colistimethate sodium on non-CF bronchiectasis with
pseudomonas aeruginosa
(preliminary report)
Source: Eur Respir J 2007; 30: Suppl. 51, 439s
Year: 2007
Long-term treatment with low-dose azithromycin reduces cough, sputum production and exacerbations in patients with idiopathic diffuse bronchiectasis
Source: Eur Respir J 2004; 24: Suppl. 48, 707s
Year: 2004
The low dose macrolides for prevention of exacerbations in non-CF bronchiectasis
Source: International Congress 2015 – Management of asthma and other respiratory diseases in primary care
Year: 2015
Anti-inflammatory effects of high-dose inhaled fluticasone versus oral prednisone in asthma exacerbations
Source: Eur Respir J 2007; 30: 1143-1149
Year: 2007
Effect of inhaled mannitol on the sputum properties in asthmatics with excessive secretions
Source: Eur Respir J 2006; 28: Suppl. 50, 666s
Year: 2006
Changes in respiratory symptoms during 48-week treatment with ARD-3150 (inhaled liposomal ciprofloxacin) in bronchiectasis: results from the ORBIT-3 and -4 studies
Source: Eur Respir J, 56 (4) 2000110; 10.1183/13993003.00110-2020
Year: 2020
Effectiveness and adherence to treatment with nebulized colistimethate sodium (Promixin®) in non-cystic fibrosis bronchiectasis colonized by pseudomonas aeruginosa (PsA)
Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical aspects and research outlook
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept